LP
ENGNW icon

LMR Partners’s enGene Therapeutics Warrants ENGNW Stock Holding History

LMR Partners’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.8K Sell
309,763
-10,924
-3% -$11.4K ﹤0.01% 1378
2026
Q1 		$811K Buy
320,687
+241,160
+303% +$715K ﹤0.01% 1017
2025
Q4 		$235K Buy
+79,527
New +$182K ﹤0.01% 1255

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

LMR Partners's ENGNW Position: Q2 2026 in Review

LMR Partners reduced its enGene Therapeutics Warrants (ENGNW) stake by 3.4% in Q2 2026, selling an estimated $11.4K and leaving 309,763 shares worth $89.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

LMR Partners first reported a position in ENGNW in Q4 2025 and has held it in 3 quarters since. The position peaked at $811K in Q1 2026. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • LMR Partners held 309,763 shares of enGene Therapeutics Warrants worth $89.8K as of Q2 2026.
  • LMR Partners sold 10,924 enGene Therapeutics Warrants shares in Q2 2026, an estimated $11.4K.
  • enGene Therapeutics Warrants made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1378 holding.
  • LMR Partners first reported a position in enGene Therapeutics Warrants in Q4 2025 and has held it in 3 quarters since.
  • LMR Partners's enGene Therapeutics Warrants position peaked at $811K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.